Protective effects of magnesium lithospermate B against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 69-76

  Hur, Kyu Yeon ^a,b,f   Kim, Soo Hyun ^b   Choi, Min Ah ^b   Williams, Darren R ^a,b,g   Lee, Yong ho ^b   Kang, Sang Won ^c   Yadav, Umesh C S ^d   Srivastava, Satish K ^d   Jung, Mankil ^a   Cho, Jin Won ^a   Kim, Sang Geon ^e   Kang, Eun Seok ^a,b   Lee, Eun Jig ^a,b   Lee, Hyun Chul ^a,b  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Ewha Womans University   (South Korea)

^d University of Texas Medical Branch School of Medicine   (United States)

^e Seoul National University   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

Diabetes mellitus; Diabetic atherosclerosis; Magnesium lithospermate B; Nrf2; Oxidative stress

Indexed keywords

ALDEHYDE REDUCTASE; MAGNESIUM LITHOSPERMATE; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ANTIOXIDANT; HERBACEOUS AGENT; LITHOSPERMATE B; NFE2L2 PROTEIN, RAT; NQO1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; ATHEROSCLEROSIS; BALLOON CATHETER; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ATHEROSCLEROSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPORTER GENE; RESTENOSIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSIENT TRANSFECTION; VASCULAR SMOOTH MUSCLE; ANIMAL; COMPLICATION; DNA RESPONSIVE ELEMENT; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ALDEHYDE REDUCTASE; ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; DIABETES MELLITUS, EXPERIMENTAL; DRUGS, CHINESE HERBAL; MALE; MUSCLE, SMOOTH, VASCULAR; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; RESPONSE ELEMENTS;

EID: 77954314390     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.01.035     Document Type: Article

References (30)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
2. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23:599-622.
3. King G.L., Loeken M.R. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 2004, 122:333-338.
4. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
5. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P., Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000, 342:154-160.
6. Cheng T.O. Danshen: a versatile Chinese herbal drug for the treatment of coronary heart disease. Int J Cardiol 2006, 113:437-438.
7. Zhou L., Zuo Z., Chow M.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005, 45:1345-1359.
8. Cheng T.O. Danshen: a popular chinese cardiac herbal drug. J Am Coll Cardiol 2006, 47:1498. [author reply 9-500].
9. Jung M., Lee H.C., Ahn C.W., et al. Effective isolation of magnesium lithospermate B and its inhibition of aldose reductase and fibronectin on mesangial cell line. Chem Pharm Bull (Tokyo) 2002, 50:1135-1136.
10. Hur K.Y., Seo H.J., Kang E.S., et al. Therapeutic effect of magnesium lithospermate B on neointimal formation after balloon-induced vascular injury. Eur J Pharmacol 2008, 586:226-233.
11. Lee G.T., Ha H., Jung M., et al. Delayed treatment with lithospermate B attenuates experimental diabetic renal injury. J Am Soc Nephrol 2003, 14:709-720.
12. Srivastava S.K., Ramana K.V., Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005, 26:380-392.
13. Akimoto Y., Kreppel L.K., Hirano H., Hart G.W. Hyperglycemia and the O-GlcNAc transferase in rat aortic smooth muscle cells: elevated expression and altered patterns of O-GlcNAcylation. Arch Biochem Biophys 2001, 389:166-175.
14. Yan S.F., Harja E., Andrassy M., Fujita T., Schmidt A.M. Protein kinase C beta/early growth response-1 pathway: a key player in ischemia, atherosclerosis, and restenosis. J Am Coll Cardiol 2006, 48:A47-55.
15. Shinmura K., Bolli R., Liu S.Q., et al. Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ Res 2002, 91:240-246.
16. Kikkawa R., Haneda M., Uzu T., Koya D., Sugimoto T., Shigeta Y. Translocation of protein kinase C alpha and zeta in rat glomerular mesangial cells cultured under high glucose conditions. Diabetologia 1994, 37:838-841.
17. Tanigawa S., Fujii M., Hou D.X. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic Biol Med 2007, 42:1690-1703.
18. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 2002, 8:1249-1256.
19. Abizaid A., Kornowski R., Mintz G.S., et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998, 32:584-589.
20. Motohashi H., Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004, 10:549-557.
21. Nishinaka T., Yabe-Nishimura C. Transcription factor Nrf2 regulates promoter activity of mouse aldose reductase (AKR1B3) gene. J Pharmacol Sci 2005, 97:43-51.
22. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
23. Ruef J., Liu S.Q., Bode C., et al. Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler Thromb Vasc Biol 2000, 20:1745-1752.
24. Rittner H.L., Hafner V., Klimiuk P.A., Szweda L.I., Goronzy J.J., Weyand C.M. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest 1999, 103:1007-1013.
25. Srivastava S., Vladykovskaya E., Barski O.A., et al. Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice. Circ Res 2009, 105:793-802.
26. Chen X.L., Dodd G., Thomas S., et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 2006, 290:H1862-H1870.
27. Levonen A.L., Inkala M., Heikura T., et al. Nrf2 gene transfer induces antioxidant enzymes and suppresses smooth muscle cell growth in vitro and reduces oxidative stress in rabbit aorta in vivo. Arterioscler Thromb Vasc Biol 2007, 27:741-747.
28. Xue M., Qian Q., Adaikalakoteswari A., Rabbani N., Babaei-Jadidi R., Thornalley P.J. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 2008, 57:2809-2817.
29. Siegel D., Gustafson D.L., Dehn D.L., et al. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 2004, 65:1238-1247.
30. Zhu H., Jia Z., Mahaney J.E., et al. The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger. Cardiovasc Toxicol 2007, 7:202-211.